Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
Spotlight - The Future of Cryopreserved Amniotic Membrane in Oculoplastic Surgery
Optometry360 Logo White
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Industry Council
    • Advisory Board
Home > Ocular Surface Disease > Higher concentration of HA artificial tears shows superior results in dry eye treatment with IPL therapy
  • Ocular Surface Disease

Higher concentration of HA artificial tears shows superior results in dry eye treatment with IPL therapy

Kelsey Moroz

Both 0.10% and 0.15% hyaluronic acid (HA)-containing artificial tears, when used in combination with intense pulsed light (IPL) therapy, are effective in treating dry eye disease (DED), with the higher concentration showing slightly better improvement in tear stability according to a study.

The study included 42 eyes treated with 0.10% HA-containing artificial tears and 40 eyes in the 0.15% HA group. Key outcomes measured included non-invasive tear break-up time (NITBUT), Schirmer II test results, ocular surface staining, and DED-related symptoms.

At the 3-month follow-up, the 0.15% HA group showed significantly better improvement in NITBUT (P = 0.023) and recovery (P = 0.039) compared to the 0.10% HA group. In addition, multiple DED-related symptoms were associated with a lack of symptom improvement in both groups (P < 0.05). A low pre-treatment NITBUT was marginally linked to no symptom improvement in the 0.10% HA group (P = 0.047).

Reference
Lee CY, Yang SF, Chen YC, et al. The Usage of Different Hyaluronic-Acid-Containing Artificial Tears and the Treatment Outcome of Intense Pulsed Light Therapy for Dry Eye Disease: A Retrospective Cohort Study. Diagnostics (Basel). 2024;14(16):1796. doi: 10.3390/diagnostics14161796. PMID: 39202284; PMCID: PMC11354216.

Share

Related Content

  • Ocular Surface Disease

Scleral lenses improve vision and symptoms across ocular surface diseases

  • Dry Eye

Spotlight on LACRIFILL®

  • Conference Roundup

CAM360 with a collagen shield provides rapid epithelial healing with better tolerability and safety than when used with bandage contact lenses

  • Conference Roundup

If your patient has recurrent chalazia, consider co-occurring Demodex blepharitis

  • Neurotrophic Keratitis

Novel anterior keratoplasty approach supports healing in refractory ocular surface disease

  • Neurotrophic Keratitis

Shelf-stable amniotic membrane shows short- and long-term improvements in ocular surface disease

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Optometry360 Logo

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon